Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$4.53 -5.4%	$5.07	$3.61 ▼ $11.09	$53.11M	1.48	187,596 shs	73,209 shs
PRAX Praxis Precision Medicines	$41.63 -1.7%	$38.82	$26.70 ▼ $91.83	$862.42M	2.61	381,048 shs	229,162 shs
SURF Surface Oncology	$1.07	$1.01	$0.56 ▼ $1.43	$65.08M	1.75	430,375 shs	N/A
SYRS Syros Pharmaceuticals	$0.03 +22.7%	$0.03	$0.02 ▼ $6.93	$724K	1.31	8.09 million shs	24,801 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	0.00%	-2.24%	+4.59%	-15.07%	-49.04%
PRAX Praxis Precision Medicines	0.00%	-4.42%	+12.76%	+12.28%	+1.53%
SURF Surface Oncology	0.00%	0.00%	0.00%	0.00%	0.00%
SYRS Syros Pharmaceuticals	0.00%	-1.35%	-29.26%	-52.17%	-99.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DTIL Precision BioSciences	4.1625 of 5 stars	3.5	3.0	0.0	4.6	0.6	1.7	1.3
PRAX Praxis Precision Medicines	2.4525 of 5 stars	4.4	2.0	0.0	0.0	1.1	1.7	0.0
SURF Surface Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	3.7157 of 5 stars	3.1	3.0	0.0	4.3	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	3.00	Buy	$47.00	937.53% Upside
PRAX Praxis Precision Medicines	2.80	Moderate Buy	$109.90	163.99% Upside
SURF Surface Oncology	0.00	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	2.20	Hold	$3.33	12,245.68% Upside

Current Analyst Ratings Breakdown

Latest DTIL, SYRS, PRAX, and SURF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/7/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/5/2025	PRAX Praxis Precision Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$26.00 ➝ $28.00
5/5/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/1/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $105.00
4/8/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $85.00
3/28/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$68.70M	0.73	N/A	N/A	$6.87 per share	0.66
PRAX Praxis Precision Medicines	$8.55M	99.18	N/A	N/A	$23.90 per share	1.74
SURF Surface Oncology	$30M	2.17	N/A	N/A	$0.81 per share	1.32
SYRS Syros Pharmaceuticals	$386K	1.88	N/A	N/A	$0.79 per share	0.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	$7.17M	-$2.01	N/A	N/A	N/A	-42.99%	-69.26%	-29.30%	7/30/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)
SURF Surface Oncology	-$63.59M	-$1.53	N/A	N/A	N/A	N/A	-107.81%	-65.57%	N/A
SYRS Syros Pharmaceuticals	-$164.57M	-$3.03	N/A	N/A	N/A	N/A	-3,369.56%	-97.04%	7/29/2025 (Estimated)

Latest DTIL, SYRS, PRAX, and SURF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SURF Surface Oncology	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.45	6.62	6.62
PRAX Praxis Precision Medicines	N/A	8.44	8.44
SURF Surface Oncology	N/A	3.60	3.60
SYRS Syros Pharmaceuticals	N/A	2.25	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
PRAX Praxis Precision Medicines	67.84%
SURF Surface Oncology	37.21%
SYRS Syros Pharmaceuticals	91.47%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	4.00%
PRAX Praxis Precision Medicines	2.70%
SURF Surface Oncology	12.00%
SYRS Syros Pharmaceuticals	12.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	200	11.09 million	10.64 million	No Data
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable
SURF Surface Oncology	35	60.82 million	53.53 million	Not Optionable
SYRS Syros Pharmaceuticals	120	26.83 million	23.54 million	Optionable

DTIL, SYRS, PRAX, and SURF Headlines

Recent News About These Companies

Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals

April 15, 2025 | msn.com

Syros Pharmaceuticals trading resumes

March 1, 2025 | markets.businessinsider.com

Syros Pharmaceuticals Plans to Wind Down Operations

March 1, 2025 | marketwatch.com

Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock

March 1, 2025 | markets.businessinsider.com

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

February 28, 2025 | businesswire.com

Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline

January 30, 2025 | msn.com

Syros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?

January 18, 2025 | bovnews.com

What’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?

January 16, 2025 | bovnews.com

SYRS’s Latest Surge: What’s Behind the Spike?

January 6, 2025 | bovnews.com

The SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines Again

January 2, 2025 | bovnews.com

Analysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?

December 31, 2024 | bovnews.com

Syros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It Appears

December 27, 2024 | bovnews.com

Syros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes Revealed

December 26, 2024 | bovnews.com

What’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?

December 14, 2024 | bovnews.com

Syros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?

December 7, 2024 | bovnews.com

Why Did Syros Pharmaceuticals Inc (SYRS) Stock Plunge -1.67% Last Week?

December 5, 2024 | bovnews.com

Nancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock

December 5, 2024 | insidertrades.com

Syros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. Wainwright

December 2, 2024 | bovnews.com

Why Is Syros Pharmaceuticals Inc (SYRS) Stock Lagging Behind -84.72% from Its 50-Day SMA?

November 29, 2024 | bovnews.com

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells $36,372.51 in Stock

November 28, 2024 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, SYRS, PRAX, and SURF Company Descriptions

Precision BioSciences NASDAQ:DTIL

$4.53 -0.26 (-5.43%)

Closing price 04:00 PM Eastern

Extended Trading

$4.68 +0.15 (+3.20%)

As of 07:54 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Praxis Precision Medicines NASDAQ:PRAX

$41.63 -0.71 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$41.66 +0.02 (+0.06%)

As of 06:12 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Surface Oncology NASDAQ:SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.

Syros Pharmaceuticals NASDAQ:SYRS

$0.03 +0.01 (+22.73%)

As of 03:48 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time